{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2017:XDAI5PMQ7K3OPLDZXLUBMSZWO5","short_pith_number":"pith:XDAI5PMQ","canonical_record":{"source":{"id":"1706.09083","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.QM","submitted_at":"2017-06-28T00:18:01Z","cross_cats_sorted":["cs.DM","q-bio.BM"],"title_canon_sha256":"8d1c024ef6a7b797d096476ad475bb55e065998cd3d73b52083ecf87e15e1bee","abstract_canon_sha256":"2cb7f63d1afb50107b10a1e0c4f1c132c40898f188a193aa0ce32344fefa4586"},"schema_version":"1.0"},"canonical_sha256":"b8c08ebd90fab6e7ac79bae8164b367742a434b15697b09e499c02e28fbb05b5","source":{"kind":"arxiv","id":"1706.09083","version":1},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1706.09083","created_at":"2026-05-18T00:11:43Z"},{"alias_kind":"arxiv_version","alias_value":"1706.09083v1","created_at":"2026-05-18T00:11:43Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1706.09083","created_at":"2026-05-18T00:11:43Z"},{"alias_kind":"pith_short_12","alias_value":"XDAI5PMQ7K3O","created_at":"2026-05-18T12:31:53Z"},{"alias_kind":"pith_short_16","alias_value":"XDAI5PMQ7K3OPLDZ","created_at":"2026-05-18T12:31:53Z"},{"alias_kind":"pith_short_8","alias_value":"XDAI5PMQ","created_at":"2026-05-18T12:31:53Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2017:XDAI5PMQ7K3OPLDZXLUBMSZWO5","target":"record","payload":{"canonical_record":{"source":{"id":"1706.09083","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.QM","submitted_at":"2017-06-28T00:18:01Z","cross_cats_sorted":["cs.DM","q-bio.BM"],"title_canon_sha256":"8d1c024ef6a7b797d096476ad475bb55e065998cd3d73b52083ecf87e15e1bee","abstract_canon_sha256":"2cb7f63d1afb50107b10a1e0c4f1c132c40898f188a193aa0ce32344fefa4586"},"schema_version":"1.0"},"canonical_sha256":"b8c08ebd90fab6e7ac79bae8164b367742a434b15697b09e499c02e28fbb05b5","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-05-18T00:11:43.391059Z","signature_b64":"IxK32sEwN7biGJ2piMus55vSicwn+Dbj208d3K4pI1/LfKictJqMHIlAFKkuAmPBrrXIfBpwz1fDaV2dwqmeDg==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"b8c08ebd90fab6e7ac79bae8164b367742a434b15697b09e499c02e28fbb05b5","last_reissued_at":"2026-05-18T00:11:43.390560Z","signature_status":"signed_v1","first_computed_at":"2026-05-18T00:11:43.390560Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"1706.09083","source_version":1,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T00:11:43Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"7QaUSVZ1njBRVeLEqX6vgvaPJ3j2cLqlR/eUSVHP2fqzw7xkk7H3MGDlwzwLgM+I+TrBG9FpqbryQ3mm+DVfBA==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-07-05T04:24:25.342498Z"},"content_sha256":"7fb2931e8ee5fdfb9e2425a446c1963b42db3fd12be92fc38d4e4442bedbd14a","schema_version":"1.0","event_id":"sha256:7fb2931e8ee5fdfb9e2425a446c1963b42db3fd12be92fc38d4e4442bedbd14a"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2017:XDAI5PMQ7K3OPLDZXLUBMSZWO5","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"Population-specific design of de-immunized protein biotherapeutics","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":["cs.DM","q-bio.BM"],"primary_cat":"q-bio.QM","authors_text":"Benjamin Schubert, Charlotta Sch\\\"arfe, Debora Marks, Oliver Kohlbacher, Pierre D\\\"onnes, Thomas Hopf","submitted_at":"2017-06-28T00:18:01Z","abstract_excerpt":"Immunogenicity is a major problem during the development of biotherapeutics since it can lead to rapid clearance of the drug and adverse reactions. The challenge for biotherapeutic design is therefore to identify mutants of the protein sequence that minimize immunogenicity in a target population whilst retaining pharmaceutical activity and protein function. Current approaches are moderately successful in designing sequences with reduced immunogenicity, but do not account for the varying frequencies of different human leucocyte antigen alleles in a specific population and in addition, since man"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1706.09083","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T00:11:43Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"cKWHPKeZWjNI5uW6wjRrejPFi4ZlJbaJ013cpgFp3GXkn2bo2gYC8r7XWiWCbRa11HIkfOx/mEUpv4mQ4DlcAA==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-07-05T04:24:25.342844Z"},"content_sha256":"f03fa37febab48ebf6a0ab799d5cca39ad087458143e4126f290d8c807567c12","schema_version":"1.0","event_id":"sha256:f03fa37febab48ebf6a0ab799d5cca39ad087458143e4126f290d8c807567c12"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/XDAI5PMQ7K3OPLDZXLUBMSZWO5/bundle.json","state_url":"https://pith.science/pith/XDAI5PMQ7K3OPLDZXLUBMSZWO5/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/XDAI5PMQ7K3OPLDZXLUBMSZWO5/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-07-05T04:24:25Z","links":{"resolver":"https://pith.science/pith/XDAI5PMQ7K3OPLDZXLUBMSZWO5","bundle":"https://pith.science/pith/XDAI5PMQ7K3OPLDZXLUBMSZWO5/bundle.json","state":"https://pith.science/pith/XDAI5PMQ7K3OPLDZXLUBMSZWO5/state.json","well_known_bundle":"https://pith.science/.well-known/pith/XDAI5PMQ7K3OPLDZXLUBMSZWO5/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2017:XDAI5PMQ7K3OPLDZXLUBMSZWO5","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"2cb7f63d1afb50107b10a1e0c4f1c132c40898f188a193aa0ce32344fefa4586","cross_cats_sorted":["cs.DM","q-bio.BM"],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.QM","submitted_at":"2017-06-28T00:18:01Z","title_canon_sha256":"8d1c024ef6a7b797d096476ad475bb55e065998cd3d73b52083ecf87e15e1bee"},"schema_version":"1.0","source":{"id":"1706.09083","kind":"arxiv","version":1}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1706.09083","created_at":"2026-05-18T00:11:43Z"},{"alias_kind":"arxiv_version","alias_value":"1706.09083v1","created_at":"2026-05-18T00:11:43Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1706.09083","created_at":"2026-05-18T00:11:43Z"},{"alias_kind":"pith_short_12","alias_value":"XDAI5PMQ7K3O","created_at":"2026-05-18T12:31:53Z"},{"alias_kind":"pith_short_16","alias_value":"XDAI5PMQ7K3OPLDZ","created_at":"2026-05-18T12:31:53Z"},{"alias_kind":"pith_short_8","alias_value":"XDAI5PMQ","created_at":"2026-05-18T12:31:53Z"}],"graph_snapshots":[{"event_id":"sha256:f03fa37febab48ebf6a0ab799d5cca39ad087458143e4126f290d8c807567c12","target":"graph","created_at":"2026-05-18T00:11:43Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"paper":{"abstract_excerpt":"Immunogenicity is a major problem during the development of biotherapeutics since it can lead to rapid clearance of the drug and adverse reactions. The challenge for biotherapeutic design is therefore to identify mutants of the protein sequence that minimize immunogenicity in a target population whilst retaining pharmaceutical activity and protein function. Current approaches are moderately successful in designing sequences with reduced immunogenicity, but do not account for the varying frequencies of different human leucocyte antigen alleles in a specific population and in addition, since man","authors_text":"Benjamin Schubert, Charlotta Sch\\\"arfe, Debora Marks, Oliver Kohlbacher, Pierre D\\\"onnes, Thomas Hopf","cross_cats":["cs.DM","q-bio.BM"],"headline":"","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.QM","submitted_at":"2017-06-28T00:18:01Z","title":"Population-specific design of de-immunized protein biotherapeutics"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1706.09083","kind":"arxiv","version":1},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:7fb2931e8ee5fdfb9e2425a446c1963b42db3fd12be92fc38d4e4442bedbd14a","target":"record","created_at":"2026-05-18T00:11:43Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"2cb7f63d1afb50107b10a1e0c4f1c132c40898f188a193aa0ce32344fefa4586","cross_cats_sorted":["cs.DM","q-bio.BM"],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.QM","submitted_at":"2017-06-28T00:18:01Z","title_canon_sha256":"8d1c024ef6a7b797d096476ad475bb55e065998cd3d73b52083ecf87e15e1bee"},"schema_version":"1.0","source":{"id":"1706.09083","kind":"arxiv","version":1}},"canonical_sha256":"b8c08ebd90fab6e7ac79bae8164b367742a434b15697b09e499c02e28fbb05b5","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"b8c08ebd90fab6e7ac79bae8164b367742a434b15697b09e499c02e28fbb05b5","first_computed_at":"2026-05-18T00:11:43.390560Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-05-18T00:11:43.390560Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"IxK32sEwN7biGJ2piMus55vSicwn+Dbj208d3K4pI1/LfKictJqMHIlAFKkuAmPBrrXIfBpwz1fDaV2dwqmeDg==","signature_status":"signed_v1","signed_at":"2026-05-18T00:11:43.391059Z","signed_message":"canonical_sha256_bytes"},"source_id":"1706.09083","source_kind":"arxiv","source_version":1}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:7fb2931e8ee5fdfb9e2425a446c1963b42db3fd12be92fc38d4e4442bedbd14a","sha256:f03fa37febab48ebf6a0ab799d5cca39ad087458143e4126f290d8c807567c12"],"state_sha256":"66ca9343b0ec8c19f933738492e8464f55e1dc98ff20a06874a01ef8fea87641"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"VZNGAja5yHttGfSn3vtq8gMK2As/MiTa5YAqcnEWBxTsGDPjxMf8loGuk4Vmke7rrWEVtsR47rQwvIp4AW8VCQ==","signed_message":"bundle_sha256_bytes","signed_at":"2026-07-05T04:24:25.344765Z","bundle_sha256":"2e6c728244dd91339655fbe0e427227aeafaa0c789d03b6b582c6a0bbc11ba21"}}